CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com
About Us
Overview
Our work in Biosimilars
Board of Directors
Executive Leadership Team
Our Stories
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Our Business
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Our Products
Global
India
Partners
Global Footprint
Our Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Investors
Newsroom
Press Releases
Company Statements
Our Stories
Media Contacts
Careers
Working With Us
Now Hiring
Contact Us
Press Releases 2017
Biocon Biologics
/
News – Posts
/
Press Releases
/
Press Releases 2017
Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs
Fri, 29-Dec-2017
Posted by: Biocon Biologics
No Comments
U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2Positive Breast and Gastric Cancers
Fri, 01-Dec-2017
Posted by: Biocon Biologics
No Comments
European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim
Fri, 01-Dec-2017
Posted by: Biocon Biologics
No Comments
Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India
Thu, 23-Nov-2017
Posted by: Biocon Biologics
No Comments
Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore
Thu, 26-Oct-2017
Posted by: Biocon Biologics
No Comments
Biocon Ranked Among Top 10 Global Pharma & Biotech Employers
Wed, 25-Oct-2017
Posted by: Biocon Biologics
No Comments
JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment
Wed, 06-Sep-2017
Posted by: Biocon Biologics
No Comments
Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore
Thu, 27-Jul-2017
Posted by: Biocon Biologics
No Comments
FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab
Fri, 14-Jul-2017
Posted by: Biocon Biologics
No Comments
Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions
Sun, 11-Jun-2017
Posted by: Biocon Biologics
No Comments
1
2